LAUSR

1. Yek C, Warner S, Wiltz JL, Sun J, Adjei S, Mancera A, et al. Risk factors for severe COVID-19 outcomes among persons aged >18 years who completed a primary COVID-19 vaccination series—465 health care facilities, United States, December 2020–October 2021. MMWR Morb Mortal Wkly Rep 2022;71:19–25. 2. Ketcham SW, Bolig TC, Molling DJ, Sjoding MW, Flanders SA, Prescott HC. Causes and circumstances of death among patients hospitalized with COVID-19: a retrospective cohort study. Ann Am Thorac Soc 2021; 18:1076–1079. 3. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20: 1135–1140. 4. Greene R, Lind S, Jantsch H, Wilson R, Lynch K, Jones R, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy. AJR Am J Roentgenol 1987;148: 501–508. 5. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1977;296:476–480. 6. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002;346:1281–1286. 7. Ryan D, Frohlich S, McLoughlin P. Pulmonary vascular dysfunction in ARDS. Ann Intensive Care 2014;4:28. 8. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020;383:120–128. 9. Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, et al. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol 2020;319:L277–L288. 10. Hariri LP, North CM, Shih AR, Israel RA, Maley JH, Villalba JA, et al. Lung histopathology in coronavirus disease 2019 as compared with severe acute respiratory syndrome and H1N1 influenza: a systematic review. Chest 2021;159:73–84. 11. Alba GA, Samokhin AO, Wang R-S, et al. Pulmonary endothelial NEDD9 and the prothrombotic pathophenotype of acute respiratory distress syndrome due to SARS-CoV-2 infection. Pulm Circ 2022;159:e12071. 12. Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med 2020;8:1201–1208. 13. Nuche J, P erez-Olivares C, Segura de la Cal T, Jim enez L opez-Guarch C, Arribas Ynsaurriaga F, Escribano Sub ıas P. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev Esp Cardiol (Engl Ed) 2020;73:775–778 14. Belge C, Quarck R, Godinas L, Montani D, Escribano Subias P, Vachi ery JL, et al. COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Res 2020;6:00520-02020. 15. Sulica R, Cefali F, Motschwiller C, Fenton R, Barroso A, Sterman D. COVID-19 in pulmonary artery hypertension (PAH) patients: observations from a large PAH center in New York City. Diagnostics (Basel) 2021;11:128. 16. Lee JD, Burger CD, Delossantos GB, Grinnan D, Ralph DD, Rayner SG, et al. A survey-based estimate of COVID-19 incidence and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension and impact on the process of care. Ann Am Thorac Soc 2020;17:1576–1582. 17. Montani D, Certain M-C, Weatherald J, Jaïs X, Bulifon S, Noel-Savina E, et al.; French PH Network PULMOTENSION Investigators. COVID-19 in patients with pulmonary hypertension: a national prospective cohort study. Am J Respir Crit Care Med 2022;206:573–583. 18. Chocron R, Galand V, Cellier J, Gendron N, Pommier T, Bory O, et al.; Critical COVID-19 France Investigators. Anticoagulation before hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study. J Am Heart Assoc 2021;10: e018624. 19. Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al.; ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021;397:2253–2263. 20. Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al.; REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021;385:777–789. 21. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al.; ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021;385:790–802. 22. Turnbull AE, Ruhl AP, Lau BM, Mendez-Tellez PA, Shanholtz CB, Needham DM. Timing of limitations in life support in acute lung injury patients: a multisite study. Crit Care Med 2014;42:296–302.